Xiaoxue Zhu

Jilin University (JLU) - First Hospital

SCHOLARLY PAPERS

1

DOWNLOADS

27

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

The Enedioic Acid Analogue 326E Alleviates MASH in Preclinical Studies and its Signatures in Patients via Dual Targeting at ACLY and PPARα

Number of pages: 62 Posted: 16 Oct 2024
Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Jilin University (JLU) - First Hospital, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Nanjing University of Chinese Medicine (NJUCM), Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Jilin University (JLU) - First Hospital, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Kunming Biomed International, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Burgeon Therapeutics Co., Ltd., Burgeon Therapeutics Co., Ltd., Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Jilin University (JLU) - Department of Hepatology, Jilin University (JLU) - First Hospital, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research, Chinese Academy of Sciences (CAS) - State Key Laboratory of Drug Research and Independent
Downloads 27 (1,055,530)

Abstract:

Loading...

Metabolic dysfunction-associated steatohepatitis, 326E, ACLY, lipogenesis, PPARα, fatty acid β-oxidation, phase 1b/2a clinical trial